If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
== Interactions == Few pharmacokinetic drug interactions have been demonstrated in vivo. The manufacturer notes potential pharmacological interactions with opioids, benzodiazepines, barbiturates, ethanol (alcohol), and other central nervous system depressants. Concurrent use of ACE inhibitors and pregabalin may increase the risk of angioedema. Pregabalin may also enhance the fluid-retaining effects of certain antidiabetic agents, such as thiazolidinediones. Pregabalin may independently increase the risk of angioedema, and this risk is further elevated when used in combination with other drugs known to increase the likelihood of angioedema. These drugs include, but are not limited to, certain L-type calcium channel blockers, ACE inhibitors, angiotensin II receptor blockers, and other agents that inhibit the renin–angiotensin–aldosterone system. The combination of pregabalin with opioids is associated with an increased risk of respiratory depression. This interaction reflects both pharmacodynamic and pharmacokinetic mechanisms: pharmacodynamically, pregabalin and opioids produce additive CNS depression, while pharmacokinetically, opioids reduce gastrointenstinal motility, which may prolong gabapentin absorption and raise its plasma concentrations, with a 2017 study finding that use of gabapentin alongside opioids carries an increased risk of opioid-related death. As pregabalin and gabapentin share the same mechanism of action (binding to the α2δ subunit of voltage-gated calcium channels), findings regarding gabapentin are considered likely applicable to pregabalin.
== Manufacturing == Remdesivir requires "70 raw materials, reagents, and catalysts" to make, and approximately "25 chemical steps." Some of the ingredients are extremely dangerous to humans, especially trimethylsilyl cyanide. The original end-to-end manufacturing process required 9 to 12 months to go from raw materials at contract manufacturers to finished product, but after restarting production in January 2020, Gilead Sciences was able to find ways to reduce the production time to six months. In January 2020, Gilead began working on restarting remdesivir production in glass-lined steel chemical reactors at its manufacturing plant in Edmonton, Alberta. On 2 February 2020, the company flew its entire stock of remdesivir, 100 kilograms in powder form (left over from Ebola research), to its filling plant in La Verne, California, to start filling vials. The Edmonton plant finished its first new batch of remdesivir in April 2020. Around the same time, fresh raw materials began to arrive from contract manufacturers reactivated by Gilead in January. Another challenge is getting remdesivir into patients despite the drug's "poor predicted solubility and poor stability." In June 2020, Ligand Pharmaceuticals revealed that Gilead has been managing those issues by mixing Ligand's proprietary excipient Captisol (based on University of Kansas research into cyclodextrin) with remdesivir at a 30:1 ratio.
=== Fatty Acid Synthesis === Fatty acid synthesis begins in the cytosol. During the first reaction, irreversible carboxylation of acetyl-CoA to malonyl-CoA is catalyzed by the biotin-dependent enzyme acetyl-CoA carboxylase (ACC). Notably, the conversion of acetyl-CoA to malonyl-CoA is the rate-limiting step of fatty acid synthesis. Acetyl-CoA carboxylase (ACC) thus represents the rate-limiting enzyme in fatty acid synthesis; ACC activity is stimulated by increasing concentrations of cytosolic citrate, and inhibited by increasing concentrations of the fatty acid palmitate. After malonyl-CoA becomes available by virtue of ACC, fatty acid synthase (FAS) is then able to complete a series of reactions to form the 16-carbon molecule palmitate. FAS is a complex, multifunctional protein containing seven different catalytic sites: acetyl transacylase, malonyl transacylase, β-ketoacyl synthase, β-ketoacyl carrier protein (ACP) reductase, 3-hydroxyacyl-ACP dehydratase, enoyl-ACP reductase, and thioesterase. These different enzymes are covalently linked within the FAS complex, allowing for intermediates to be handled efficiently from one active site to another without leaving the assembly. After the completion of the first reaction by ACC, fatty acid synthesis thus continues on the FAS complex. During the second reaction of fatty acid synthesis, acetyl transacylase and malonyl transacylase catalyze the formation of acetyl-ACP and malonyl-ACP, respectively.
In 1979, the ANC's National Executive Committee had indeed endorsed a programme which included mass popular mobilisation inside South Africa, and its literature contained calls to reject the black local authorities. In addition, ANC president Oliver Tambo famously called for opponents of apartheid to make South Africa "ungovernable". On 8 January 1984, Tambo's annual statement to ANC members had included the entreaty:We should direct our collective might to rendering the enemy's instruments of authority unworkable. To march forward must mean that we advance against the regime's organs of state-power, creating conditions in which the country becomes increasingly ungovernable... Having rejected the community councils by boycotting the elections, we should not allow them to be imposed on us. We do not want them. We must ensure that they cease to exist. Where administration boards take over their functions, then these must be destroyed too.
Sources: en.wikipedia.org
Alpha defensins are a family of mammalian defensin peptides of the alpha subfamily. They are also known as cryptdins and are produced within the small bowel. Cryptdin is a portmanteau of crypt and defensin. Defensins are 2-6 kDa, cationic, antimicrobial peptides active against many Gram-negative and Gram-positive bacteria, fungi, and enveloped viruses, containing three pairs of intramolecular disulfide bonds. On the basis of their size and pattern of disulfide bonding, mammalian defensins are classified into alpha, beta and theta categories. Alpha-defensins, which have been identified in humans, monkeys and several rodent species, are particularly abundant in neutrophils, certain macrophage populations and Paneth cells of the small intestine. Defensins are produced constitutively and/or in response to microbial products or proinflammatory cytokines. Some defensins are also called corticostatins because they inhibit corticotropin-stimulated corticosteroid production. The mechanism(s) by which microorganisms are killed and/or inactivated by defensins is not understood completely. However, it is generally believed that killing is a consequence of disruption of the microbial membrane. The polar topology of defensins, with spatially separated charged and hydrophobic regions, allows them to insert themselves into the phospholipid membranes so that their hydrophobic regions are buried within the lipid membrane interior and their charged (mostly cationic) regions interact with anionic phospholipid head groups and water.
=== 25th anniversary update === In November 2023, for the 25th anniversary of Half-Life, Valve updated the Steam version to revert content to its original 1998 state, fix long-standing bugs, and add content including the Half-Life: Uplink demo, four new multiplayer maps, Steam Deck support, rendering improvements, and support for 4K resolution monitors. Valve also released an hour-long documentary on the creation of Half-Life, featuring commentary from the original developers, designers and artists. Two days after the release, Half-Life reached 33,471 concurrent players on Steam, its highest-ever number.
=== Time resolved laser fluorescence spectroscopy === Time-resolved laser fluorescence spectroscopy is a sensitive spectroscopic method able to investigate the formation of different complex species in sub-micro molar concentrations. Thanks to the great spectroscopic properties of some metal cations representatives of actinides and lanthanides, fluorescence analyses by laser excitation of ion energy levels can be carried out on monophasic and biphasic solutions. The fluorescence evolution resulting from the ion energy transitions is generally followed as a function of ligand concentration in monophasic titration experiments. The bathochromic shift of the fluorescence spectra are due to the ligand complexation. According to the postulated complexation model and the Slope Analysis on the experimental data, the stoichiometry of the major complexes can be determined. Moreover, the cumulative stability constants
Normally, amino acids do not provide the bulk of fuel substrates. However, in times of glycolytic or ATP crisis, amino acids can convert into pyruvate, acetyl-CoA, and citric acid cycle intermediates. This is useful during strenuous exercise or starvation as it provides faster ATP than fatty acids; however, it comes at the expense of risking protein catabolism (such as the breakdown of muscle tissue) to maintain the free amino acid pool.
When the British missed capturing President Paul Kruger, as he escaped Pretoria during its fall in June 1900, a Melbourne Punch cartoon depicted how the War could be won, using the Kelly Gang. The convictions and executions of two Australian lieutenants, Harry Harbord Morant and Peter Handcock in 1902, and the imprisonment of a third, George Witton, had minimal impact on the Australian public at the time. The controversial court-martial saw the three convicted of executing prisoners under their authority. After the war though, Australians joined an empire-wide campaign that saw Witton released from jail. Much later, some Australians came to see the execution of Morant and Handcock as instances of wrongfully executed Australians, as illustrated in the 1980 Australian film Breaker Morant. Up to 50 Aboriginal Australians served in the Boer War as trackers. Such is the lack of information available it is even uncertain as to whether they returned to Australia after the war. When the Australian contingents returned the trackers may not have been allowed back to Australia due to the White Australia Policy.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。